INSUBCONTINENT EXCLUSIVE:
generic oral solids and dermatology businesses has been mutually called off.
The stock ended down 3% at Rs 380.85 on Friday
During the session, it briefly traded in the green before declining again.
Brokerages see the termination of the deal as a setback for the
The transaction was cancelled as the approval from the US Federal Trade Commission could not be obtained within the anticipated timelines
target price to Rs 345 from Rs 450
the deal called off, the stock is now exposed to the US FDA risk on two key plants (1) Unit IV flag, post inspection in Nov-2019, is yet to
Credit Suisse and HSBC, Investec believes that Sandoz deal termination is a setback but the stock is attractively valued and no longer has
hurt ARBN (Aurobindo Pharma) stock over last 12 months
concurred, saying that the cancellation of the deal is a sentimental negative but it reduces the anticipated financial burden from the
It has lowered target price on the stock to Rs 645 from Rs 780.
